AstraZeneca and Daiichi Sankyo’s Enhertu Receives US FDA Approval in Early Breast Cancer for Two Indications

Why It Matters

The dual approvals broaden the therapeutic arsenal for HER2‑positive early breast cancer, offering higher response rates and a potential new standard of care, while delivering a sizable revenue boost for both partners.

Key Takeaways

• FDA greenlights Enhertu+THP for neoadjuvant HER2+ stage II/III
• Pathologic complete response reached 67.3% vs 56.3% with standard chemo
• Enhertu monotherapy cut invasive disease‑free survival risk by 53%
• 3‑year IDFS 92.4% for Enhertu vs 83.7% for T‑DM1
• Milestone triggers $155 million payment from AstraZeneca to Daiichi Sankyo

Pulse Analysis

The FDA’s decision to expand Enhertu into early‑stage HER2‑positive breast cancer marks a pivotal shift in how oncologists approach neoadjuvant therapy. Traditional regimens rely on anthracycline‑based chemotherapy plus HER2‑targeted antibodies, but the DESTINY‑Breast11 trial demonstrated that the antibody‑drug conjugate paired with trastuzumab‑pertuzumab achieved a 67.3% pathologic complete response, outpacing the 56.3% benchmark of standard care. This higher pCR rate not only improves surgical outcomes but also correlates with longer event‑free survival, positioning Enhertu as a compelling alternative for patients seeking less toxic, more targeted options.

In the adjuvant arena, the DESTINY‑Breast05 data reinforce Enhertu’s potency after surgery and HER2‑directed therapy. A 53% relative reduction in invasive disease‑free survival events and a 92.4% three‑year IDFS rate signal a robust durability that could reshape post‑operative treatment algorithms. Clinicians now have evidence that a single‑agent ADC can outperform trastuzumab emtansine, the previous standard, potentially simplifying treatment pathways and reducing cumulative chemotherapy exposure.

Beyond clinical impact, the approval carries significant commercial implications. The $155 million milestone payment underscores the financial stakes of co‑development agreements and highlights the growing market value of next‑generation ADCs. As insurers and health systems evaluate cost‑effectiveness, the demonstrated efficacy gains may justify premium pricing, accelerating revenue streams for both AstraZeneca and Daiichi Sankyo. Moreover, the success of Enhertu in early disease could spur further investigations into ADCs across other tumor types, reinforcing the strategic importance of antibody‑drug conjugates in the broader oncology pipeline.